{
    "2021-03-10": [
        [
            {
                "time": "",
                "original_text": "贝达药业：股东凯铭投资解除质押239万股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯铭投资",
                        "解除质押",
                        "239万股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：股东凯铭投资质押延期购回511万股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯铭投资",
                        "质押延期",
                        "511万股"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：凯铭投资解押239万股及质押的511万股延期购回",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯铭投资",
                        "解押",
                        "239万股",
                        "质押延期",
                        "511万股"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "如何解决医药原始创新能力不足？强化基础研究成关键",
                "features": {
                    "keywords": [
                        "医药",
                        "原始创新",
                        "基础研究"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}